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ABSTRACT
Aggregation of the protein α-synuclein (α-syn) into insoluble intracellular assemblies 
termed Lewy bodies (LBs) is thought to be a critical pathogenic event in LB diseases such 
as Parkinson’s disease and dementia with LBs. In LB diseases, the majority of α-syn is 
phosphorylated at serine 129 (pS129), suggesting this is an important disease-related 
post-translational modification (PTM). However, PTMs do not typically occur in isolation, and 
phosphorylation at the proximal tyrosine 125 (pY125) residue has received considerable 
attention and has been inconsistently reported to be present in LBs. Furthermore, the proximity 
of Y125 to S129 means that some pS129 antibodies may have epitopes that include Y125, in 
which case phosphorylation of Y125 will impede recognition of α-syn. This would potentially 
lead to underestimating LB pathology burdens if pY125 occurs alongside pS129. To address the 
apparent controversy in the literature regarding the detection of pY125, we investigated its 
presence in LB pathology. We generated pS129 antibodies whose epitope includes or does 
not include Y125 and compared the extent of α-syn pathology recognized in mouse 
models of α-synucleinopathies, human brain tissue lysates and fixed post-mortem brain 
tissues. Our study demonstrated no difference in α-syn pathology recognized between pS129 
antibodies, irrespective of whether Y125 was part of the epitope or not. Furthermore, evaluation 
with pY125 antibodies whose epitope does not include S129 demonstrated no labelling of LB 
pathology. This study reconciles disparate results in the literature and demonstrates pY125 is not 
a key component of LB pathology in murine models or human tissues in idiopathic LB diseases.
Keywords
Alpha-synuclein, Parkinson’s disease, phosphorylation, Lewy bodies, dementia with Lewy bodies.
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INTRODUCTION
Aggregation of the protein α-synuclein (α-syn) into insoluble assemblies within vulnerable 
neurons is thought to be a critical event in the pathogenesis of Lewy body diseases (LBD) 
such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) [21, 24]. Evidence from 
genetic studies suggested that mutations or duplications in the α-syn gene cause familial 
PD [4, 15].
Despite the apparent importance of α-syn aggregation in LBD, many studies report a poor 
relationship between the severity of LB pathology and clinical phenotype [22], or neuronal 
loss [3]. Numerous species of α-syn have been described with assumed different relevance 
to pathological neurodegeneration [21]; however, most studies of LBD employ antibodies 
that recognize both native and pathological species. α-Syn is post-translationally modified 
(PTM) [19, 20], and α-syn phosphorylated at serine 129 (pS129) is abundant in LBs, suggesting 
an association with disease states [2, 9]. 
Due to the abundance of pS129-α-syn abundance in LB pathology [2, 9], the region around 
pS129 has received considerable attention and several studies have investigated other 
C-terminal phosphorylation sites [5-6, 10, 12-13, 16, 18].  Of these sites, α-syn can be 
phosphorylated at Y125, Y133, and Y136.  While several studies looked into the role of 
some of these modifications and how they interact to affect oligomerization of the protein in 
vitro, only pY125 was investigated in brain tissue [2, 5, 12]. In one immunohistochemical study, 
pY125 has been found within LBs in a familial PD case with G51D mutation [12]; whereas 
another study reported detecting pY125-α-syn in brain lysates from a Drosophila model of 
PD but failed to detect it in human brain tissues [5]. Similarly, a study using proteomic and mass 
spectrometry analyses of α-syn from patients with DLB reported that pS129 is the 
dominant pathological modification and failed to detect pY125 [2]. Several in vitro studies 
have also explored the role of Y125 phosphorylation [5, 10]. One study reported pY125 
inhibits α-syn aggregation implying a neuroprotective role [10]; whereas a previous in vitro 
study using nuclear magnetic resonance spectroscopy reported pY125 is a priming event 
for pS129, suggesting it may be an important precipitating event in the genesis of α-syn 
aggregation [13]. Therefore, there is a pressing need to characterize whether pY125 occurs 
alongside pS129 in LBs in human brain tissue and animal models of α-synucleinopathy.  
PTMs in LBD have typically been investigated in isolation, usually focused on pS129. However, A
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PTMs are unlikely to occur in such an isolated manner under physiological conditions, and the 
same molecule of α-syn may be phosphorylated at numerous sites. Y125 is a 
phosphorylation site of sufficient proximity to S129 and therefore, can be part of the epitope 
for many available antibodies against pS129-α-syn. Precise mapping of the epitope for 
these anti-pS129-α-syn antibodies is needed to provide information on whether they will 
only recognize pS129-α-synuclein when Y125 is not phosphorylated, but such information 
is lacking since the precise epitope for most commercial pS129 antibodies is not disclosed. 
Therefore, previous antibody-based studies of pS129 may have been limited by only 
detecting aggregates that are singly phosphorylated and not recognizing aggregates that 
contain doubly phosphorylated α-syn at Y125 and S129.
In the present study, we sought to identify whether pY125 is present in α-syn aggregates 
that characterize LB pathology. Using a panel of four in-house developed and thoroughly 
characterized antibodies as well as three commercial antibodies, we evaluated the pathological 
relevance of pY125 and pS129 α-syn in LB pathology.  
MATERIALS AND METHODS
Generation and characterization of anti pS129-α-syn antibodies
Generation of mouse monoclonal antibodies was performed using hybridoma technology as 
recently described [8]. Animal procedures were carried out in accordance with Laboratory 
Animal Research Center (LARC), Qatar University (QU), Qatar, according to the QU institutional 
ethical rules and regulations and approved by QU—IACUC & IBC. 
Epitope mapping of antibodies
To map the epitopes for our mAbs, we performed alanine scanning experiments, a widely used 
site-directed mutagenesis approach. Synthetic eleven amino acid long peptides spanning 
residues (124-134) were used (Supplementary Table 1). 384-well black MaxiSorb plate (Nunc) 
was coated with 500 ng/well of the peptides in NaHCO3 and incubated overnight at 37°C in dry 
conditions. The following day, the plate was blocked with blocking buffer (PBST containing 2.25% 
gelatin) for 1 hr at RT. The plate was then washed three times with PBST, and the mAbs were 
added at 100 ng/ml for 1 hr. 
Tissue culture of HEK 293 human embryonic kidney cellsA
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 HEK cells were grown in Dulbecco’s MEM- high glucose (Gibco BRL, Rockville, MD) 
supplemented by 15% fetal bovine serum (Gibco BRL, Rockville, MD), 1% penicillin-streptomycin 
(Gibco BRL, Rockville, MD) and incubated at 37°C in a 5% CO2/95% air humidified incubator. After 
plating HEK cells overnight in 6-well plates, cells were transfected with 2µg of wild type -syn 
plasmid DNA by lipofectamine 3000 reagent (Invitrogen, Waltham, MA). One group of -syn 
expressing HEK cells was similarly transfected again with 4µg of -syn seeds (preparation 
described in supplementary methods) the following day. HEK cells were lysed, 48 hours post 
transfection, initially with 1% Triton X-100 in 50mM Tris, 150mM NaCl (pH 7.6) containing 
protease and phosphatase inhibitors to obtain soluble fractions. The pellet was further lysed with 
1% SDS in 50mM Tris, 150mM NaCl (pH 7.6) with complete inhibitors to attain insoluble 
fractions. Protein concentration was determined by BCA protein assay (Pierce) prior to analysis 
on 12% SDS-PAGE and immunoprobing. Primary antibodies used in this study are summarized 
(supplementary table 2).
Immunofluorescence analysis of mouse brain sections
Male wild-type C57BI6/C3H mice 2–4 month old (Jackson Laboratory, Bar Harbor, Main) 
were used. These have been previously undergone stereotaxic injections with α-syn 
preformed fibrils phosphorylated at serine 129, as described previously [11]. Animals were 
anesthetized by isoflurane surgical anesthesia and perfused intracardially with ice-cold PBS 
followed by 4% paraformaldehyde in PBS and post-fixed overnight. Brains were frozen in 
iso-pentane at −45 °C and stored at −80°C. Fluorescent immunohistochemistry was performed in 
free-floating sections of 35 μm. The sections were treated with antigen retrieval solution 
(citrate buffer, pH = 6) at 80 °C for 30 min followed by treatment with Proteinase K (PK) 
(Sigma-Aldrich, USA) 5 μg/ml in PBS for 10 min at 25°C. Immunohistochemical staining with 
the anti-β Tubulin III antibody (TUJ1; Sigma monoclonal) was performed at a working dilution of 
1:1000. 
Preparation of human brain lysates
Frozen post-mortem samples of the frontal cerebral cortex from clinically diagnosed PD (n=2), 
DLB cases (n = 2), or age-matched controls (n = 2) were obtained from Newcastle Brain Tissue 
Resource and processed as previously described [8, 25]. Briefly, tissues were homogenized on ice A
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in 5 volumes of TBS buffer (50 mM Tris-HCl, pH 7.4, 175 mM NaCl) containing 5 mM EDTA and 
cocktail of protease phosphatase inhibitors, and then centrifuged for 30 min at 3000 x g at 4°C. 
The resulting supernatants subsequently referred to as the “aqueous soluble fraction”. Pellets 
were re-suspended and homogenized in buffer containing the mild detergent cell-lytic and 150 
mM NaCl and centrifuged at 3000 x g at 4°C, with the resulting supernatant subsequently 
referred to as “detergent soluble fraction”. The resulting detergent insoluble pellets were 
solubilized in 8 M Urea/5% SDS and will subsequently be referred to as the “insoluble fraction”. 
Total protein concentration was measured using the Pierce BCA assay.
Immunoblotting of human brain lysates
10 μg of urea-soluble brain lysates, as well as 50 ng of recombinant human α-syn, or 
pS129-α-syn (supplementary methods), were mixed with loading buffer (250 mM Tris-HCl, 
pH 6.8, 30% glycerol, 0.02% bromophenol blue) and then separated on 12% SDS-PAGE gels. 
The gels were then transferred to nitrocellulose membranes in transfer buffer (25mM Tris, 192 
mM glycine, 20% methanol). The membranes were boiled for 5 min in PBS and then blocked for 1 
hour with 5% BSA prepared in PBST. The blots were then incubated with the antibodies at 100 
ng/ml followed by secondary antibody (1:20K dilution) at RT. Immunoreactive bands were 
visualized using the SuperSignal West Pico Chemiluminescent Substrate Kit (Pierce, cat # 34080).
Immunohistochemistry of human post-mortem tissue
We obtained 6 μm formalin-fixed paraffin-embedded post-mortem human brain tissue from 
the cingulate gyrus and substantia nigra for immunohistochemical and immunofluorescent 
staining (Table 1). Optimal epitope unmasking was empirically determined, with heat-mediated 
antigen retrieval in boiling citrate pH6 followed by five minutes in formic acid found to confer a 
modestly better signal compared to EDTA pH8 and citrate pH6 without formic acid for all 
antibodies. 5B9 (1µg/ml), 6H5 (1µg/ml), 9G1 (200ng/ml), PS129 (in-house; 100ng/ml), ab51253 
(Abcam; 2µg/ml), pY125 (Abcam ab10789, ab131466; both 2µg/ml) and pY133 (Abcam ab51104; 
5µg/ml) were incubated for one hour at room temperature.  Immunohistochemical staining 
used the Menarini MenaPath X-Cell Plus HRP detection kit with Menarini purple chromagen 
(Menarini Diagnostics, Berkshire, UK).
For immunofluorescent analysis, antigen retrieval was performed using citrate pH6 and formic A
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acid as before, and sections were blocked in 10% normal goat serum for one hour at room 
temperature. Primary antibodies (PS129, 1µg/ml; ab51253, 4µg/ml; pY125, 10µg/ml; pY133, 
10µg/ml) were suspended in 10% normal goat serum and incubated overnight at 4°C. Secondary 
antibodies for PS129 and ab51253 (goat anti-mouse Alexa Fluor 488, Thermo Fisher #A28175; 
goat anti-rabbit Alexa Fluor 594 #R37117) or for PS129/pY125 and pS129/pY133 (goat 
anti-mouse Alexa Fluor 647, Thermo Fisher #A21241 and goat anti-rabbit Alexa Fluor 594, 
Thermo Fisher #A1101) were diluted 1:100 in 10% normal goat serum for one hour at room 
temperature, before being incubated in 1% Sudan Black B and mounted in ProLong Gold 
Anti-Fade (PS129 and ab51253 used ProLong Gold with added DAPI). Fluorescent images were 
visualized on a Nikon Eclipse 90i microscope for PS129 and ab51253; and on a Leica SP8 confocal 
microscope for PS129/pY125 and PS129/pY133.    
RESULTS
Epitope mapping of monoclonal antibodies against pS129-α-syn
Our group has previously generated three mouse monoclonal antibodies (mAbs; 5B9, 6H5, 
and 9G1) against pS129-α-syn [8]. These were thoroughly characterized in combination with 
our previously generated mAb (PS129) [14] and the commercial mAb (ab51253; abcam). The 
specificity of all antibodies towards pS129-α-syn was validated. All antibodies showed 
nanomolar affinity towards pS129-α-syn and did not cross-react with WT-α-syn [8]. Epitope 
mapping of the antibodies showed that 5B9 and 6H5 map to amino acids (128-131) (Figure 1 A, 
B), whereas 9G1 and ab51253 were mapped to amino acids (127-130) (Figure 1 C-D). PS129 had a 
slightly different epitope mapped to residues (124-129) (Figure 1 E). Syn-1, which has an epitope 
between amino acids 91-99 [27] did not react with any of the peptides and was included as a 
negative control (Figure 1 F). We confirmed that all four antibodies can recognize the 
doubly-phosphorylated peptide at Y125 and S129 (Figure 2 A-C, E). On the contrary, PS129 only 
recognized the pS129 peptide and failed to recognize it when it is also phosphorylated at Y125 
(Figure 2 D). This was expected given that Y125 residue falls within its epitope (Figure 1 E) and 
hence, phosphorylation on this site would disrupt the binding epitope (details in supplementary 
results). It is worth noting that Y133 is not part of the epitope for the five mAbs tested, meaning 
that these mAbs can potentially detect pS129-α-syn if it is also phosphorylated at Y133. A
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Further analysis will be required to validate the sensitivity of these mAbs to 
multiply-phosphorylated pS129-α-syn at Y125 and Y133. 
Detection of pY125- and pS129-α-syn in α-syn expressing HEK cells
To verify that our mAbs detect pathologically relevant accumulations in a cell model system, 
we tested the antibodies using an experimental model for seeded aggregation of α-syn in 
HEK293 cells. α-Syn phosphorylation and its corresponding seeding-dependent 
aggregation were induced in α-syn expressing HEK cells, where phosphorylation of α-syn 
was promoted after a consecutive transfection of WT-α-syn plasmid DNA and α-syn 
seeds. Immunoblotting of cell lysates showed that pS129-α-syn was detected for all the 
mAbs tested (Figure 3 A). Noticeable increased levels of insoluble pS129-α-syn was seen 
in the plasmid and seed transfected cells compared to no detection in the non-transfected 
(negative control) and plasmid-transfected cells, with the latter indicating the 
seeding-dependent phosphorylation importance.  On the other hand, soluble fractions 
showed comparable levels in the two transfected group using all indicated pS129-α-syn 
specific antibodies. We have also evaluated two commercially available antibodies 
specific for pY125-α-syn (ab10789 and ab124955; Abcam). These antibodies can 
recognize pY125-α-syn when it is also phosphorylated at S129 (S129 is not part of their 
epitopes; supplementary figure 1). Both antibodies did not detect pY125-α-syn in our cell 
model (Figure 3 B). Total α-syn levels, as detected using Syn-1, was seen in all transfected 
groups in both soluble and insoluble fractions (Figure 3 B).  
Investigating the presence of pY125- and pS129-α-syn in brain sections of PD 
mouse model
Immunofluorescent staining was performed in the brain sections of C57BI6/C3H mice who 
had received stereotaxic injection of pre-formed α-syn fibrils (α-syn PFFs) in the right 
dorsal striatum, as previously described [11]. At 60 dpi, midbrain sections were analyzed by 
immunofluorescence using the indicated pS129-α-syn specific antibodies. All the five 
antibodies were able to detect cytoplasmic accumulations of pS129-α-syn surrounded by 
TUJ1-stained neurons (Figure 4 A), with no distinction in staining between antibodies capable 
of recognizing pY125/pS129-α-syn and an antibody that can only recognize pS129-α-syn. 
These accumulations were not observed upon staining with the two antibodies specific for A
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pY125-α-syn (Figure 4B). Our observations indicate the absence of pY125-α-syn in a tissue 
from PD mouse model. Although pY125-α-syn was still undetectable in tissues stained without 
antigen-retrieval methods (data not shown), results need to be interpreted with caution for the 
known effects antigen-retrieval methods could have on an epitope. 
Immunoblotting of human brain lysates to evaluate the presence of pY125-α-syn 
Next, we used our newly developed antibodies to confirm the detection of pS129-α-syn 
pathology and explore the presence of pY125 -α-syn in post-mortem human brain lysates. 
Brain lysates were homogenized in a sequential manner to obtain the aqueous-soluble fraction, 
followed by detergent-soluble fraction, and eventually urea-soluble fraction. We have 
previously reported the accumulation of pS129-α-syn in urea-soluble fractions of human 
brain lysates using ELISA and immunoblotting [26]. It is detected to a lesser extent in 
detergent-soluble fractions but not in aqueous-soluble fractions [26] (Supplementary Figure 2). 
We subjected urea-soluble fractions from the frontal lobes of two PD cases, two DLB cases, and 
two healthy control cases to western blotting analyses. As expected, immunoblotting analyses 
showed accumulation of pS129-α-syn in all diseased cases (Figure 5 A). These bands were 
not present in healthy controls, whereas Syn-1 did show immunoreactivity (Figure 5 B), 
presumably representing the native, physiological protein (Figure 5). The above results further 
confirmed the antibodies’ ability to detect pS129-α-syn pathology in brain samples from 
patients with synucleinopathies (PD, DLB), and that this immunoreactivity was 
phosphorylation specific at S129. Notably, we did not observe any significant differences in the 
signal recognized by the four antibodies that can recognize pY125/pS129-α-syn (5B9, 
6H5, 9G1, and ab51253) in comparison to PS129. Moreover, the two antibodies specific 
for pY125-α-syn did not detect any α-syn pathology in the brain lysates tested (Figure 5B and 
Supplementary Figure 2), suggesting that pY125-α-syn does not appear to be present in LB 
pathology.
pY125-α-syn is not a component of Lewy bodies in post-mortem human brain 
tissues 
To further evaluate the pathological relevance of pY125- and pS129-α-syn in LBs from 
brains of patients with synucleinopathies, immunohistochemical staining of 5B9, 6H5, and 9G1 
in the substantia nigra of an aged control (Case 9) and Parkinson’s disease dementia (PDD; Case A
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1) case, and in the cingulate gyrus of a control (Case 9) and mixed DLB and Alzheimer’s disease 
(AD) case (mixed AD/DLB; Case 7). The antibodies 5B9, 6H5, 9G1, as well as PS129, labelled the 
circumference of intracellular inclusions only in the cases with LBs diseases (Figure 6). Antibody 
9G1 gave a slightly different pattern of staining, with some labelling of apparent axonal and/or 
dendritic processes (Figure 6), possibly due to its cross-reactivity with hyperphosphorylated 
neurofilament protein [8]. Importantly, antibodies that can recognize pY125/pS129-α-syn 
did not stain distinct or more abundant pathology than the antibody (PS129) that can only 
recognize pS129, suggesting that pS129-α-syn is the dominant modification and that 
pY125-α-syn does not exist in LBs (Figure 7). 
To further test the hypothesis that pY125 is minimally present in LBs and neurites, 
immunohistochemical staining was carried out using anti- pY125-α-syn antibodies (ab10789 
and ab124955; Abcam). Staining of brain tissue with LBs diseases from cingulate gyrus with both 
antibodies revealed flame-like profiles reminiscent of neurofibrillary tangles but no LB-type 
profiles (Figure 8 A, B, C). To determine specificity of this staining, we pre-incubated both 
antibodies with the immunizing peptide (ab17030; 10µg/ml), which eliminated staining of 
flame-like bodies, indicating specific staining by the antibody (Figure 8 D). 
Moreover, we performed co-staining of ab10789/ab124955 and PS129 in cingulate gyrus and 
substantia nigra of one PDD, four DLB and three mixed DLB/AD (Table 1). Ps129 
immunoreactivity was observed in a cortical LB in the cingulate gyrus of Case 6, but no 
co-localization with HP-tau or pY125 (Figure 9 Bi-Biv). Similarly, A midbrain Lewy body in the 
substantia nigra of Case 1 shows a pS129-positive “doughnut” structure, but only weak 
co-localization with HP-tau and pY125 (Ci-Civ). We observed flame-like bodies recognized by anti- 
pY125-α-syn antibodies that were morphologically similar to neurofibrillary tangles. As these 
flame-like bodies were observed in regions with proclivity to developing neurofibrillary tangles, 
we tested whether these staining were detecting hyper-phosphorylated tau (HP-tau) in 
neurofibrillary tangles. Immunofluorescence indicated flame-like profiles immunoreactive for 
anti-pY125-α-syn antibodies (ab10789 and ab124955) were co-localized with the HP-tau 
antibody, AT8 in the cingulate gyrus of Case 6 (Figure 9 Ai-Aiv). Similar observations were made 
in the hippocampus of Case 6, where co-localization between HP-tau and pY125-α-syn 
was observed, but not pS129 (Figure 9 Di-Div). Notably, the only instances where A
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anti-pY125-α-syn antibodies showed staining in LBs pathology was only when similar levels of 
AT8 positivity were observed (Figure 9 Ci-Civ). Whilst it is possible that pY125-α-syn is 
present in neurofibrillary tangles, this seems unlikely as antibodies with epitopes unlikely 
to be affected by phosphorylation at this reside, such as Syn-1, have not been reported to 
recognize neurofibrillary tangles. Therefore, as neurofibrillary tangles contain tau 
phosphorylated at many residues [17], we speculate that this staining may represent 
cross-reactivity with a phosphorylated tau epitope. However, irrespective of whether 
pY125-α-syn is or is not in neurofibrillary tangles, it does not appear to be present in LBs 
based on the present findings. We finally examined whether the other phosphorylation site 
proximal to S129, Y133, was phosphorylated in α-syn aggregates using a commercially available 
antibody (ab51104; Supplementary table 1). Immunofluorescence showed faint staining only at 
concentration much higher than that recommended by manufacturer (Supplementary Figure 3), 
whereas immunoblotting of human brain lysates did not show any pathology (Supplementary 
Figure 4).   Further analyses with more specific immunological tools are needed to evaluate the 
presence of pY133-α-syn in LBs.
DISCUSSION
α-Syn is known to undergo several post-translational modifications in PD and related disorders, 
the most abundant being phosphorylation at serine 129 [2, 19, 20]. Over the past decade, 
immunoreactivity to pS129-α-syn has emerged as a hallmark feature of PD and related 
synucleinopathies. This raised the question of whether pS129-α-syn plays an important 
role in initiating misfolding, and aggregation of α-syn in the disease state. Various in vitro and 
in vivo studies that investigated the effect of phosphorylation of α-syn at S129 have failed 
to reach a consensus as to the role played by this modification [17]; nevertheless, it is a 
consistent marker of LB pathology in PD and other synucleinopathies.
PTMs such as pS129-α-syn might not occur in isolation, and few studies have evaluated 
the presence of different PTMs and how these may interact in the etiopathology of LBD. Besides 
its phosphorylation at S129, a-syn has been shown to undergo phosphorylation at several 
tyrosine residues in the C-terminal region, namely Y125, Y133, and Y136 in vitro. Out of these 
three residues, phosphorylation at Y125 is thought to be more relevant [1, 6, 16, 18] and is the 
only phosphorylation site that has been detected in vivo. The few studies that have studied A
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pY125 in LBDs have reported discrepant findings, with one reporting it as present within LBs [10] 
and another demonstrating a reduction in pY125 in whole tissue lysates from LBD brain tissue 
compared to aged controls [5]. This discrepancy is in part due to the lack of immunological 
tools needed to address this question. Moreover, the proximity of Y125 to S129 is such 
that the epitope of pS129-α-syn antibodies may also span Y125, meaning such antibodies 
would only recognize α-syn when it is not phosphorylated at Y125. Nevertheless, several 
in vitro studies investigated the effect of pY125 and how it affects oligomerization of α-syn 
through interactions with proximal residue pS129, suggesting that pY125 may act as a priming 
event for efficient phosphorylation of S129 [13]. Given the putative importance of 
pS129-α-syn in LB pathology, investigating proximal phospho-epitopes is crucial to further 
understanding of synucleinopathies. 
To overcome the discrepant findings regarding the presence of pY125-α-syn in LB 
pathology, we used a combination of newly developed in-house and commercial antibodies 
and conducted a comprehensive study of its presence in cellular and rodent models and human 
post-mortem brain tissue. In this study, we have demonstrated that pY125-α-syn is not a 
component of α-syn inclusions in cell model systems, rodents injected with α-syn fibrils and 
post-mortem human brain tissue. In contrast, pS129-α-syn is consistently observed 
across all systems and tissues. These findings suggest that pY125 is not a major or 
critical component of LBs.
We performed epitope mapping experiments for the antibodies used herein and showed that 
three out of four in-house antibodies as well as ab51253 are specific for pS129-α-syn and their 
reactivity towards it does not decrease if pS129-α-syn is also phosphorylated at Y125. This is 
largely attributed to Y125 not being covered in the epitope for these antibodies. It should be 
noted, however, that these epitopes might not fully represent the exposed epitope in a 
full-length protein depending on its folding patterns and will therefore require further analysis. 
Using two commercial pY125-α-syn antibodies we noted immunoreactivity in 
neurofibrillary tangles and co-localization with hyper-phosphorylated tau. Whilst it is 
possible that pY125-α-syn is a component of neurofibrillary tangles, previous studies have 
not reported α-syn-immunoreactive neurofibrillary tangles, and it is unlikely this would 
have been unreported given the importance of such a finding for the interaction of 
pathologies and the growing interest in multiple pathologies in age-associated A
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neurodegeneration. We speculate that pY125-α-syn antibodies may be cross-reacting 
with the extensive phosphorylation in tau pathology. Furthermore, we noted that previous 
reports of pY125-α-syn in LB pathology were observed in the CA1 sector of the 
hippocampus, a region where the authors also noted some co-localization of 
phosphorylated tau and α-syn, in a case carrying a G51D mutation [12]. Therefore, one 
could speculate that a plausible explanation of the discrepant findings is that cases harboring 
G51D mutations have inclusions consisting of α-syn and tau, and that pY125-α-syn 
antibodies are detecting tau in these inclusions. However, an equally plausible explanation is 
that, as G51D mutations are unique amongst disease-causing mutations of α-syn as they 
inhibit aggregation [7, 23] and have atypical neuropathological features [12], the discrepant 
findings simply underline the differences between idiopathic LB disease and those observed in 
individuals with G51D mutations. 
CONCLUSIONS
In conclusion, we have addressed the discrepancy in the literature regarding the role of 
pY125-α-syn in LB pathology. Using a panel of in-house developed and commercial 
antibodies, we have demonstrated that unlike pS129-α-syn, pY125 is not a major 
component of α-syn inclusions in cell or rodent model systems or post-mortem brain tissue 
from LBD cases. However, current tools to investigate pY125-α-syn may cross-react with 
phosphorylated residues in tau pathology, indicating these tools may be sub-optimal for 
identifying immunopositivity in inclusions in post-mortem brain tissue from individuals with 
age-associated neurodegeneration given the high prevalence of multiple pathologies in 
these populations. The present findings have important implications for understanding the 
genesis and etiology of α-syn pathology and methods for the study of alternative PTMs in 
LBD.
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LB – Lewy body
LBD – Lewy body disease
mAb – monoclonal antibody
PD – parkinson’s disease
PFFs – pre-formed fibrils 
pS129--syn – phosphorylated -syn at serine 129
PTM – post-translational modifications
pY125--syn– phosphorylated -syn at tyrosine 125
Tables’ and Figures’ Legends 
Table 1. Demographic details of cases used in post-mortem studies. “Braak NFT” 
refers to neurofibrillary tau pathology stage, “McKeith LB” refers to Lewy body pathology stage.
Figure 1. Epitope mapping of the antibodies 
Using indirect ELISA, peptides (Supplementary table 1) were coated on 384-well plate and 
detected with indicated antibodies. Bar chart for each antibody is shown above and the expected 
epitope is marked in red dash-lined selections (a-e). Syn 1 (f), which has an epitope between 
amino acids 91-99 was included as a negative control. RLU/10-1 sec = relative light units per tenth 
of a second. Error bars represent the mean of three independent experiments.
Figure 2. Assessing the reactivity of pS129-α-syn mAbs towards doubly 
phosphorylated-α-syn peptide. 
Using inhibition ELISA, these antibodies were pre-incubated with the 4 different peptides: 
AYEMPpSEEGYQ, ApYEMPSEEGYQ, ApYEMPpSEEGYQ, or AYEMPSEEGYQ which 
are abbreviated, pS129, pY125/pS129, pY125, and S129 respectively. The 
peptide-antibody mixture was used to detect pre-coated pS129-α-syn. Peptides were 
used at 50, 100, or 200 µM. Bar graph charts showing the optical density at 450 nm (OD, 
Y-axis) obtained upon incubation with the corresponding peptide (X-axis) for (A) 5B9, (B) 6H5, (C) 
9G1, (D) PS129, or (E) ab51253. No signal indicates strong mAb/peptide binding. Error bars 
represent the mean of three independent experiments.A
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Figure 3. Immunoblotting analysis of the antibodies in HEK293 cell model.
Analysis of α-syn- expressing HEK293 cells after transfection with α-syn seeds. Cell 
lysates were run on 12% SDS-PAGE and immunoprobed with indicated antibodies 
against pS129-α-syn (A), or pY125-α-syn (B). Syn-1 was included as a positive control (B) and 
β-Actin as a loading control (B). 
Figure 4. Immunofluorescence staining of brain sections from PD mouse model 
Brain sections from mice injected with α-syn pre-formed fibrils were stained with monoclonal 
antibodies specific for (A) pS129 α-syn or (B) pY125-α-syn. α-Syn accumulations were stained 
positive (green) in the striatal (6H5, 9G1, pS129), or midbrain (5B9, ab51253, ab10789, 
ab124955) region of the brain. (A) TUJ1 (red) or DAT (red) were used as neuronal markers.
Figure 5. Western blotting analysis of human brain lysates from healthy controls, 
PD, or DLB.
Samples from the frontal cerebral cortex of healthy controls (n=2) as well as clinically diagnosed 
PD (n=2) or DLB (n=2) patients have been analyzed on 12% SDS-PAGE, along with 50 
ng of the recombinant proteins (WT-α-syn or pS129-α-syn). The gel was transferred into 
nitrocellulose membrane for western blotting analysis. The blots were then probed using 
the indicated antibodies againt (A) pS129-α-syn, or (B) pY125-α-syn. Syn-1 was included 
as a positive control (B) and β-Actin as a loading control (B). 
Figure 6. Immunohistochemical staining of human brain tissues. Images were 
obtained in control (Case 9) and PD (Case 1) SN (substantia nigra); and in control (Case 9) and 
DLB (Case 7) CG (cingulate gyrus). Scale bars = 50 µm.
Figure 7: Co-labelling of PS129 (aa124-129) and ab51253 (aa127-130). 
Immunofluorescence in PD substantia nigra (Case 1) demonstrates that there is no difference in 
staining abundance or intensity if an antibody capable of recognizing pY125 and pS129 is used 
(ab51253) compared to an antibody that only recognizes pS129 (PS129). Scale bar = 50 µm.  
 
Figure 8.  Immunohistochemistry with ab10789 (pY125-α-syn) in the cingulate gyrus of A
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a DLB case. (Case 5) demonstrated “flame bodies” (A) that were also observed in the same case 
with ab124955 (pY125-α-syn; B). Neurofibrillary tangles were clearly labelled by ab124955 
(pY125-α-syn) in the hippocampus of a mixed AD/DLB case (Case 8; C), and this signal 
was eliminated by pre-incubation of ab124955 (pY125-α-syn) with the immunizing peptide 
for pY125 (ab17030; D). Scale bars 50 µm (A&B), 200 µm (C&D).   
Figure 9.  Co-localization of hyper-phosphorylated tau (AT8) with ab124955 
(pY125-α-syn) and in-house mAb PS129. Neuropil threads in the cingulate gyrus of Case 6 
show co-localization of HP-tau and pY125, but not pS129 (Ai-Aiv). A cortical LB in the cingulate 
gyrus of Case 6 shows pS129 immunoreactivity, but no co-localization with HP-tau or pY125 
(Bi-Biv). A midbrain Lewy body in the substantia nigra of Case 1 shows a pS129-positive 
“doughnut” structure, but only weak co-localization with HP-tau and pY125 (Ci-Civ). 
Neurofibrillary tangles in the hippocampus of Case 6 show co-localization between HP-tau and 
pY125, but not pS129 (Di-Div). Scale bars Ai-Civ = 5 µm; Di-Div = 10 µm.  
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Table 1 
 
Case ID Diagnosis Sex Age Braak NFT McKeith LB 
Case 1 PDD M 76 2 Neocortical 
Case 2 DLB F 78 3 Neocortical 
Case 3 DLB M 74 4 Neocortical 
Case 4 DLB M 81 4 Neocortical 
Case 5 DLB M 80 4 Neocortical 
Case 6 Mixed DLB/AD M 83 6 Neocortical 
Case 7 Mixed DLB/AD F 91 6 Limbic 
Case 8 Mixed DLB/AD M 77 6 Neocortical 
Case 9 Control F 90 2 No LB 
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